20-F/A: Prenetics Global Limited: IM8 Drives Strong Revenue Growth

Prenetics Global Limited's amended annual report details a strategic pivot to a consumer health platform, with its flagship IM8 brand achieving $60.1 million in revenue and $120 million ARR in its first full year.

Summary

• Prenetics Global Limited has filed an amended annual report (Form 20-F/A) for the fiscal year ended December 31, 2025, focusing on revisions to non-IFRS financial disclosures and equity-accounted investee details.
• The company has strategically transformed into a consumer health and longevity platform, with its flagship brand, IM8, co-founded with David Beckham, generating $60.1 million in revenue and reaching $120 million in annualized revenue run-rate (ARR) by December 2025.
• Total revenue from continuing operations surged by 480% to $92.4 million in 2025, driven by IM8's performance and the inclusion of Europa's distribution business.
• The company divested non-core assets, including ACT Genomics and Insighta, to concentrate resources on IM8.
• Capital markets initiatives in 2025 included an equity offering of approximately $44 million and a voluntary warrant exchange program.
• Significant global ambassador partnerships were established in 2025-2026 with athletes like Aryna Sabalenka, Ollie Bearman, and Giannis Antetokounmpo, who are also shareholders.
• The company reported a net loss of $39.98 million for 2025, an improvement from $49.81 million in 2024, with adjusted EBITDA loss of $18.1 million.
• Investments were made in digital assets (primarily Bitcoin) and financial assets, totaling approximately $74.4 million in 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as cautiously optimistic, highlighting significant revenue growth and strategic transformation, but tempered by ongoing losses and the inherent risks of a rapidly scaling consumer health business.

Positives

• IM8 brand achieved $60.1 million in revenue and $120 million ARR in its first full fiscal year (2025), demonstrating rapid market adoption.
• Total revenue from continuing operations increased by 480% to $92.4 million in 2025.
• Gross profit from continuing operations increased by 426% to $48.8 million in 2025.
• Strategic divestitures of non-core assets (ACT Genomics, Europa 3PL, Insighta) have streamlined operations and generated capital.
• Successful equity offering in October 2025 raised approximately $44 million.
• Strong global ambassador partnerships with high-profile athletes who are also shareholders align financial interests.
• The company is investing in clinical trials to validate product efficacy, a differentiator in the VMS category.
• AI-driven operations are enhancing creative production efficiency and customer acquisition strategies.

Negatives

• The company reported a net loss of $39.98 million for the year ended December 31, 2025.
• Adjusted EBITDA loss was $18.1 million for 2025.
• Selling and marketing expenses increased significantly to $35.5 million in 2025, representing 38% of revenue, as the company invests in growth.
• An impairment loss of $6.8 million was recognized for goodwill allocated to the Europa cash-generating unit.
• The company made substantial investments in digital assets ($54.4 million) and financial assets ($20.0 million) in 2025, which are subject to market volatility.
• The fair value loss on warrant liabilities was $17.9 million in 2025.
• The company's cash balance decreased from $52.3 million at the end of 2024 to $32.1 million at the end of 2025.
• The company's ability to convert customers into paying subscribers and retain them is critical and could adversely affect revenue if retention declines.

Risks

• Reliance on third-party manufacturers and distributors for production and distribution.
• Potential for supply chain disruptions or inability to obtain raw materials in required quantities.
• Intense competition in the consumer health and wellness market from established brands and new entrants.
• Failure to maintain product quality, innovation, or consumer trust could adversely affect competitive position.
• Regulatory frameworks governing dietary supplements vary by jurisdiction, requiring compliance with diverse regulations.
• The company's investments in digital assets are subject to significant market price volatility.
• The effectiveness of marketing initiatives and management of customer acquisition costs are critical for long-term sustainability.
• The company's ability to successfully manage its cost structure, including freight, marketing, and logistics, is important for profitability.

Future Outlook

The company expects its gross margin profile to improve to over 60% in 2026 following the divestiture of the Europa business. Selling and marketing expenses are expected to increase in absolute terms as the company invests in customer acquisition and market expansion, but are anticipated to stabilize or decline as a percentage of revenue over time. Research and development expenditures are expected to remain disciplined and aligned with the product roadmap. Administrative and other operating expenses are expected to increase in the near term due to scaling operations and public company requirements, but are projected to benefit from operating leverage in the longer term.

Management Comments

• Management uses ARR to monitor the growth trajectory of the IM8 brand, and believes it provides investors with a consistent measure of the brand's revenue scale as it has grown since launch.
• Management believes that adjusted EBITDA is helpful to investors as they provide useful information to understand our core financial and operating performance from period to period because they exclude certain items that may not be indicative of our business performance, including non-cash and/or non-recurring items.
• Management believes that our AI capabilities represent a durable competitive advantage that legacy supplement brands cannot easily replicate, and we expect it to be a primary driver of operating leverage as we scale toward profitability.
• Management believes our existing facilities are sufficient for our current needs, and we will obtain additional facilities, principally through leasing, to accommodate future expansion plans as needed.
• Management believes that our existing cash and cash equivalents, together with proceeds from financing activities, will be sufficient to meet our operating working capital requirements, and capital expenditures at least for the next twelve months.

Industry Context

StockSavvy.ai notes that Prenetics' strategic shift towards a consumer health and longevity platform, exemplified by the rapid growth of its IM8 brand, aligns with broader industry trends favoring science-backed wellness products and direct-to-consumer models. The company's emphasis on AI-driven operations and clinical validation positions it to compete in a crowded market, though challenges remain in managing costs and achieving profitability.

Comparison to Industry Standards

• IM8's trajectory of achieving $60.1 million in revenue and $120 million ARR within its first twelve months is described as 'without precedent in the global supplement industry'.
• The company claims that its roster of equity-aligned athlete shareholders across multiple sports is unparalleled in the consumer health sector.
• Prenetics states that very few companies in the Vitamins, Minerals and Supplements (VMS) category conduct product-level randomized controlled trials, and fewer still run multiple concurrent trials, positioning their R&D investment as a differentiator.
• The company's organization-wide AI adoption initiative, requiring every employee to build a functional AI agent, is presented as a unique standard in the consumer health industry.

Related Party Transactions

• David Beckham is a co-founding partner of IM8 and an equity holder.
• Global ambassadors Aryna Sabalenka, Ollie Bearman, and Giannis Antetokounmpo are also shareholders of Prenetics.
• The company's executive team made approximately $2.75 million in open market share purchases in Q4 2025 and Q1 2026.

Stakeholder Impact

• Shareholders: The company's strategic transformation, capital raises, and performance of IM8 are key to shareholder value. The share repurchase program authorized in March 2026 signals management's belief in undervaluation.
• Employees: The company's focus on AI proficiency and use across the organization, including a company-wide AI agent initiative, suggests a culture of innovation and efficiency that could impact employee roles and development.
• Customers: The focus on science-backed products, clinical validation, and AI-driven personalization aims to enhance customer trust and product efficacy.
• Suppliers: Reliance on third-party manufacturers and distributors necessitates strong relationships and risk mitigation strategies for supply chain continuity.

Next Steps

• Launch a minimum of two new SKUs by the end of 2026, targeting multi-billion dollar addressable categories.
• Continue to deepen integration between IM8 and CircleDNA platforms.
• Execute market-specific localization efforts across Japan, Germany, France, Spain, Hong Kong, and Australia in 2026.
• Selectively expand into new geographies where strong demand for premium health and longevity products is identified.
• Continue to optimize subscription mix and pricing to improve unit economics and strengthen long-term revenue visibility.
• Continue to invest in research and development to expand the product portfolio across complementary categories within health, wellness, and longevity.
• Diversify marketing channels into YouTube, TikTok, and AppLovin in 2026.

Key Dates

Recommendation

The company demonstrates impressive growth with its IM8 brand and a clear strategic direction. However, the continued net losses, significant investments in volatile digital assets, and the inherent risks of scaling a consumer health business warrant a cautious approach. While the growth trajectory is positive, the path to sustained profitability and the impact of market volatility on its investments suggest a 'hold' recommendation pending further evidence of consistent financial performance and risk management.

Keywords

Consumer Health, Longevity, Dietary Supplements, IM8, Genomic Testing, CircleDNA, AI, Clinical Trials